Josh Jennings
Stock Analyst at Morgan Stanley
(2.60)
# 2,287
Out of 5,022 analysts
14
Total ratings
54.55%
Success rate
18.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Josh Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCBO Docebo | Maintains: Overweight | $49 → $53 | $26.82 | +97.61% | 5 | Nov 10, 2023 | |
| PODD Insulet | Maintains: Outperform | $350 → $300 | $318.30 | -5.75% | 3 | Aug 9, 2023 | |
| BFLY Butterfly Network | Initiates: Outperform | $20 | $2.29 | +773.36% | 1 | Jun 21, 2021 | |
| MDWD MediWound | Initiates: Outperform | $63 | $18.52 | +240.17% | 1 | Sep 28, 2017 | |
| CTSO Cytosorbents | Initiates: Outperform | $7 | $0.92 | +659.38% | 1 | Jun 7, 2017 | |
| EW Edwards Lifesciences | Maintains: Outperform | $43 → $40 | $73.36 | -45.47% | 3 | Dec 7, 2016 |
Docebo
Nov 10, 2023
Maintains: Overweight
Price Target: $49 → $53
Current: $26.82
Upside: +97.61%
Insulet
Aug 9, 2023
Maintains: Outperform
Price Target: $350 → $300
Current: $318.30
Upside: -5.75%
Butterfly Network
Jun 21, 2021
Initiates: Outperform
Price Target: $20
Current: $2.29
Upside: +773.36%
MediWound
Sep 28, 2017
Initiates: Outperform
Price Target: $63
Current: $18.52
Upside: +240.17%
Cytosorbents
Jun 7, 2017
Initiates: Outperform
Price Target: $7
Current: $0.92
Upside: +659.38%
Edwards Lifesciences
Dec 7, 2016
Maintains: Outperform
Price Target: $43 → $40
Current: $73.36
Upside: -45.47%